BioNTech is ending a mid-stage trial of its experimental personalized mRNA cancer vaccine, autogene cevumeran, after an independent committee concluded it was unlikely to improve survival in patients with high-risk, mid-stage colorectal cancer. The Phase 2 study enrolled patients who had undergone surgery and chemotherapy but still had detectable circulating tumor DNA (ctDNA), testing whether the vaccine could prevent recurrence. The committee also identified a numerical imbalance in overall survival between the vaccine and control groups; Reuters reports this likely reflected more deaths in the vaccine arm, although the magnitude was unclear.
BioNTech halts mRNA colorectal cancer vaccine trial after safety review (Reuters)
0